Randy M Burd
- Associate Vice President, Global Research Alliances
- Assistant Director, Distance - Global Initiatives
- Professor, Nutritional Sciences
- Professor, BIO5 Institute
- Bart Cardon Teaching Fellow
- The goal of the teaching academy is to promote, recognize, discuss and celebrate teaching excellence, toward the goal of the continual improvement of the College academic programs. The inaugural class of six members was chosen from College faculty who have won national, regional, university or major College awards for teaching excellence, and has provided extraordinary service to the teaching mission of the College. Since then, we have inducted new members into our academy to further extend our teaching mission., Spring 2011
No activities entered.
Nutrigeno Disease Prv+InNSC 475 (Fall 2016)
Nutrigeno Disease Prv+InNSC 575 (Fall 2016)
Innovating:Creating the FutureENTR 485 (Spring 2016)
Innovating:Creating the FutureENTR 485 (Fall 2015)
Nutrigeno Disease Prv+InNSC 475 (Fall 2015)
Nutrigeno Disease Prv+InNSC 575 (Fall 2015)
Nutrigeno Disease Prv+InNSC 475 (Fall 2014)
Nutrigeno Disease Prv+InNSC 575 (Fall 2014)
Nutrigeno Disease Prv+InNSC 475 (Fall 2013)
Nutrigeno Disease Prv+InNSC 575 (Fall 2013)
- Burd, R. M. (2013). Entrepreneurial strategies for public higher education creating value for Arizona. Is Higher Education Ready for Arizona's Future.More infoMars, M.M., & Burd, R. (2013). , 102nd Arizona Town Hall Report. Edited by Gary Rhoades and Jenny J. Lee, pp. 136-155, 2013
- Randy Burd, . (2014). Opportunities and Challenges: Research and Innovation in the Life Sciences. In Advances in the Study of Entrepreneurship, Innovation & Economic Growth(pp 125-140). Emerald Group Publishing Limited.
- Burd, R., & Panayi, N. D. (2014). Short Communication; Somatomedin C. Atlas Genet Cytogenet Oncol Haematol, 18(6), 378-380.More infoAtlas Genet Cytogenet Oncol Haematol - 2014 number 06
- Morgan-Bathke, M., Harris, Z. I., Arnett, D. G., Klein, R. R., Burd, R., Ann, D. K., & Limesand, K. H. (2014). The Rapalogue, CCI-779, improves salivary gland function following radiation. PloS one, 9(12), e113183.More infoThe standard of care for head and neck cancer typically includes surgical resection of the tumor followed by targeted head and neck radiation. However depending on tumor location and stage, some cases may not require surgical resection while others may be treated with chemoradiation. Unfortunately, these radiation treatments cause chronic negative side effects for patients. These side effects are associated with damage to surrounding normal salivary gland tissue and include xerostomia, changes in taste and malnutrition. The underlying mechanisms of chronic radiation-induced salivary gland dysfunction are unknown, however, in rodent models persistently elevated proliferation is correlated with reduced stimulated salivary flow. The rapalogue, CCI-779, has been used in other cell systems to induce autophagy and reduce proliferation, therefore the aim of this study was to determine if CCI-779 could be utilized to ameliorate chronic radiation-induced salivary gland dysfunction. Four to six week old Atg5f/f; Aqp5-Cre, Atg5+/+; Aqp5-Cre and FVB mice were treated with targeted head and neck radiation. FVB mice were treated with CCI-779, chloroquine, or DMSO post-radiation. Stimulated salivary flow rates were determined and parotid and submandibular salivary gland tissues were collected for analyses. Mice with a defect in autophagy, via a conditional knockout of Atg5 in the salivary glands, display increased compensatory proliferation in the acinar cell compartment and hypertrophy at 24-72 hours following radiation. FVB mice treated with post-therapy CCI-779 have significant improvements in salivary gland physiology as determined by stimulated salivary flow rates, proliferation indices and amylase production and secretion. Consequently, post-radiation use of CCI-779 allows for improvement of salivary gland function and reestablishment of glandular homeostasis. As CCI-779 is already FDA approved for other uses, it could have a secondary use to alleviate the chronic side effects in head and neck cancer patients who have completed anti-tumor therapy.
- Morgan-Bathke, M., Hill, G. A., Harris, Z. I., Lin, H. H., Chibly, A. M., Klein, R. R., Burd, R., Ann, D. K., & Limesand, K. H. (2014). Autophagy correlates with maintenance of salivary gland function following radiation. Scientific reports, 4, 5206.More infoThe current standard of care for head and neck cancer includes surgical resection of the tumor followed by targeted head and neck radiation. This radiotherapy results in a multitude of negative side effects in adjacent normal tissues. Autophagy is a cellular mechanism that could be targeted to ameliorate these side effects based on its role in cellular homeostasis. In this study, we utilized Atg5(f/f);Aqp5-Cre mice which harbor a conditional knockout of Atg5, in salivary acinar cells. These autophagy-deficient mice display increased radiosensitivity. Treatment of wild-type mice with radiation did not robustly induce autophagy following radiotherapy, however, using a model of preserved salivary gland function by IGF-1-treatment prior to irradiation, we demonstrate increased autophagosome formation 6-8 hours following radiation. Additionally, administration of IGF-1 to Atg5(f/f);Aqp5-Cre mice did not preserve physiological function. Thus, autophagy appears to play a beneficial role in salivary glands following radiation and pharmacological induction of autophagy could alleviate the negative side effects associated with therapy for head and neck cancer.
- Hingle, M., Yoon, D., Fowler, J., Kobourov, S., Schneider, M. L., Falk, D., & Burd, R. (2013). Collection and visualization of dietary behavior and reasons for eating using Twitter. Journal of medical Internet research, 15(6).More infoIncreasing an individual's awareness and understanding of their dietary habits and reasons for eating may help facilitate positive dietary changes. Mobile technologies allow individuals to record diet-related behavior in real time from any location; however, the most popular software applications lack empirical evidence supporting their efficacy as health promotion tools.
- Mars, M. M., & Burd, R. M. (2013). Impact over revenue: Toward a social entrepreneurship model for university technology transfer. Journal of Entrepreneurship and Organization Management, 2(1), 1-7.
- Mars, M. M., Burd, R. M., & Panayi, N. D. (2013). The promise of digital (mobile) health in cancer prevention and treatment 9 (5), 613-617.. Future Oncology/Future Medicine, 9(5), 613-617.
- Panayi, N. D., Mars, M. M., & Burd, R. (2013). The promise of digital (mobile) health in cancer prevention and treatment. Future oncology (London, England), 9(5).
- Mars, M. M., & Burd, R. M. (2013, Summer). Entrepreneurial strategies for public higher education creating value for Arizona. In Gary Rhoades and Jenny J. Lee (Eds.). Is Higher Education Ready for Arizona’s Future?. In 102nd Arizona Town Hall, 102, 136-155.
- Burd, R. (2014, May). International Collaborations (Organizer). International Partners Day. Tucson, AZ.
- Burd, R. (2014, November). Innovation and Research (Organizer). International Week Symposium.
- Burd, R. (2014, October). Invited Member. Extreme Water Events Workshop.
- Burd, R. M. (2014, Summer). Building Networks for International Collaborations.. Consortium for North American Higher Education Collaboration (CONAHEC) 20th Annual Meeting. Tucson: CONAHEC.
- Burd, R. M. (2013, Spring). Mechanisms of therapeutic resistance in melanoma cells adapted to low pH. Overcoming Therapeutic Resistance, Annual Meeting of the Society for Thermal Medicine. Aruba: Society for Thermal Medicine.More infoSession Chair
- Burd, R. M. (2013, Summer). Novel agents inhibiting tumour growth and overcoming drug resistance. Inhibiting tumour growth and overcoming drug resistance, 4th International Conference RAHMS, Recent Advances in Health and Medical Sciences. Cyprus.More infoInvited Presentation and Session Chair
- Burd, R. M., Manley-Casimir, S., & Smith, L. (2013, Fall). Priorities for International Collaboration in the North American Region: Perspectives from CONAHEC Members. Congreso de las Americas 2013. Monterrey, MX: Congresso de las Americas.More infoThe Consortium for North American Higher Education Collaboration (CONAHEC) is a membership-based not for profit organization which promotes international collaboration among its 175+ member institutions and organizations. This presentation draws upon the frontline experiences and perspectives of a representative from one Canadian, one U.S. and one Mexican CONAHEC member institution. Each representative has substantial experience in driving their own institution’s international collaboration agenda in a variety of areas, including mobility, international research collaboration and technology transfer. Priority areas and issues of importance to the future of international higher education collaboration in the North American context and between the region and partners in the rest of the world will be presented and exchanged with the audience in this interactive session.
- Harris, Z., Donovan, M. G., Branco, G. M., Limesand, K. H., & Burd, R. (2016. Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy(p. 48).More infoReplacing current refractory treatments for melanoma with new prevention and therapeutic approaches is crucial in order to successfully treat this aggressive cancer form. Melanoma develops from neural crest cells, which express tyrosinase - a key enzyme in the pigmentation pathway. The tyrosinase enzyme is highly active in melanoma cells and metabolizes polyphenolic compounds; tyrosinase expression thus makes feasible a target for polyphenol-based therapies. For example, quercetin (3,3',4',5,7-pentahydroxyflavone) is a highly ubiquitous and well-classified dietary polyphenol found in various fruits, vegetables, and other plant products including onions, broccoli, kale, oranges, blueberries, apples, and tea. Quercetin has demonstrated antiproliferative and proapoptotic activity in various cancer cell types. Quercetin is readily metabolized by tyrosinase into various compounds that promote anticancer activity; additionally, given that tyrosinase expression increases during tumorigenesis, and its activity is associated with pigmentation changes in both early- and late-stage melanocytic lesions, it suggests that quercetin can be used to target melanoma. In this review, we explore the potential of quercetin as an anti-melanoma agent utilizing and extrapolating on evidence from previous in vitro studies in various human malignant cell lines and propose a "four-focus area strategy" to develop quercetin as a targeted anti-melanoma compound for use as either a preventative or therapeutic agent. The four areas of focus include utilizing quercetin to (i) modulate cellular bioreduction potential and associated signaling cascades, (ii) affect transcription of relevant genes, (iii) regulate epigenetic processes, and (iv) develop effective combination therapies and delivery modalities/protocols. In general, quercetin could be used to exploit tyrosinase activity to prevent, and/or treat, melanoma with minimal additional side effects.